Wedbush removed Ascendis Pharma from its Best Ideas List due to its investment price discipline.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASND:
- Ascendis Pharma downgraded to Equal Weight from Overweight at Morgan Stanley
- Ascendis Pharma price target lowered to $92 from $132 at BofA
- Ascendis Pharma Craters after Disappointing Drug News
- Ascendis Pharma downgraded at Credit Suisse after FDA find deficiencies in NDA
- Ascendis Pharma downgraded to Neutral from Outperform at Credit Suisse